switch semaglutide to tirzepatide Switching from Tirzepatide: What You Need to Know Switching from Semaglutide to Tirzepatide

Safety Profile, Tolerability, and Who Should Consider This Treatment Mounjaro is generally well-tolerated, with the most common adverse events being gastrointestinal (nausea, vomiting, constipation, diarrhea)

It has not yet received MHRA marketing authorisation, so there is no approved Summary of Product Characteristics

Researchers took notice when patients taking GLP-1s for diabetes also experienced significant weight loss, and in 2014, the FDA approved the first GLP-1 to treat obesity

People with chronic inflammation, autoimmune diseases, or pain syndromes often report significant improvements without harsh medication